Esthesioneuroblastoma in children and adolescent: experience on 11 cases with literature review.

Abstract

Esthesioneuroblastoma is a rare tumor of the olfactory epithelium. This report analyzed 11 children and adolescents treated in a single institution between 1982 and 2002. For 9 patients, therapy consisted of an initial course of chemotherapy before surgical resection and postoperative radiotherapy, for 1 patient an initial course of chemotherapy before radiotherapy and for another resection before radiotherapy with no chemotherapy. Response to chemotherapy was assessed in 9 patients of whom 6 achieved a complete or a partial remission. Ten patients are long-term survivors. The 5-year actuarial disease-free survival and overall survival rate was 91% (95% confidence interval, 62%-98%). Our study indicates that esthesioneuroblastoma is sensitive to chemotherapy and supports the role of combined modalities including neoadjuvant chemotherapy, surgery, and radiation therapy.

• Authors: Maria El Kababri, Jean L Habrand, Dominique Valteau-Couanet, Nathalie Gaspar, Christelle Dufour, Odile Oberlin
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 36 Issue 2 Pg. 91-5 (Mar 2014) ISSN: 1536-3678 [Electronic] United States
• PMID: 24390450 (Publication Type: Journal Article)

Topics

• Adolescent
• Child
• Child, Preschool
• Combined Modality Therapy
• Esthesioneuroblastoma, Olfactory (mortality, pathology, therapy)
• Female
• Humans
• Infant
• Kaplan-Meier Estimate
• Male
• Nasal Cavity (pathology)
• Nose Neoplasms (mortality, pathology, therapy)
• Treatment Outcome